文献速递妇科

地诺孕素治疗症状性子宫腺肌病患者的结果及其停药情况:一项前瞻性队列研究

Results of dienogest treatment and its discontinuation in patients with symptomatic adenomyosis: a prospective cohort study.
PubMed 文献 · Reprod Biomed Online · 2025-03-04

一项前瞻性队列研究纳入125例经阴道超声或磁共振诊断的子宫腺肌病绝经前患者,所有患者接受地诺孕素治疗6个月后停药3个月,每3个月评估症状、超声及弹性成像。结果显示地诺孕素可缓解症状,痛经更严重或合并子宫内膜瘤者痛经改善更明显,弥漫性腺肌病及合并肌瘤者反应较差;停药后部分复发,症状更重和病灶硬度更高是复发因素。

要点

  • 地诺孕素治疗6个月可缓解子宫腺肌病相关痛经和月经过多。
  • 痛经更严重或合并子宫内膜瘤者痛经改善更明显(均P≤0.042)。
  • 停药后症状更重和病灶硬度更高者复发风险更高(均P≤0.017)。

核心结论

  • 痛经和月经过多更严重的子宫腺肌病患者可能从地诺孕素治疗中获益最大,但停药后复发风险也更高,尤其病灶纤维化程度高时。
  • 作者认为,仅痛经严重、月经过多严重和病灶硬度较高的患者可能需要长期用药,其他患者可暂停每日用药。

研究设计与样本

  • 前瞻性队列研究,纳入125例经阴道超声、磁共振或两者诊断的子宫腺肌病绝经前患者。
  • 所有患者接受经阴道超声弹性成像检查并测量病灶硬度。
  • 所有患者服用地诺孕素(品牌或仿制)6个月,随后嘱停药3个月。
  • 自治疗开始至停药后3个月,每3个月评估经阴道超声、弹性成像及症状,并测量子宫大小、病灶硬度和血红蛋白水平。

主要发现

  • 地诺孕素治疗使症状缓解。
  • 痛经更严重或合并子宫内膜瘤的患者痛经改善更明显(均P≤0.042)。
  • 弥漫性腺肌病和合并肌瘤的患者反应较差。
  • 停药导致部分患者复发,症状更严重和病灶硬度更高被确定为症状复发的因素(均P≤0.017)。

临床怎么用

  • 作者认为,仅痛经严重、月经过多严重和病灶硬度较高的患者可能需要长期用药,其他患者可暂停每日用药。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

RESEARCH QUESTION: Do any factors in patients with symptomatic adenomyosis contribute to the greater alleviation of dysmenorrhoea and heavy menstrual bleeding (HMB) after treatment with dienogest, and what are the risk factors, if any, for recurrence if the dienogest treatment is discontinued? DESIGN: One hundred and twenty-five premenopausal patients diagnosed with adenomyosis by transvaginal ultrasound (TVUS), magnetic resonance imaging, or both. All patients underwent an ultrasound elastographic (TVESG) examination, and lesional stiffness was measured. All patients took dienogest (either branded or generic) for 6 months and were then instructed to stop for 3 months. Every 3 months after the start of treatment until 3 months after stopping, TVUS and TVESG examinations and symptoms were evaluated. Uterine size, lesional stiffness and haemoglobin levels were also measured. RESULTS: Treatment with dienogest resulted in symptom relief. Patients with more severe dysmenorrhoea or co-existing endometrioma had greater improvement in dysmenorrhoea (both P ≤ 0.042), but those with diffuse adenomyosis and co-existing fibroids responded less well. Discontinuation of the treatment causes relapse in some patients, and more severe symptoms and higher lesional stiffness were identified as factors for symptom recurrence (both P ≤ 0.017). CONCLUSIONS: Patients with adenomyosis with more severe dysmenorrhoea and HMB may benefit most from dienogest treatment, but also face higher recurrence risk if the treatment is discontinued, especially when their lesions are highly fibrotic. Therefore, only patients with severe dysmenorrhoea, severe HMB and higher lesional stiffness may require long-term medication, whereas others may take a break from daily medications.

来源:Reprod Biomed Online,查看原文。版权归原作者所有。

引用

  1. Shen M, Liu X, Ding D, et al. Results of dienogest treatment and its discontinuation in patients with symptomatic adenomyosis: a prospective cohort study. Reprod Biomed Online. 2025. PMID: 40582022. doi:10.1016/j.rbmo.2025.104880

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。